CIMAvax-EGF + CIMAher Combined Immunotherapy
Coordinated therapeutic cancer vaccine plus anti-EGFR monoclonal antibody program for advanced non-small cell lung cancer.
Product information
Combined CIMAvax-EGF therapeutic vaccine and CIMAher (nimotuzumab) anti-EGFR monoclonal antibody program. Coordinated by CIM, Havana.
Indications
Advanced non-small cell lung cancer (NSCLC) as combined immunotherapy.
Formulation
Coordinated program of therapeutic vaccine and monoclonal antibody.
Administration
As prescribed by oncology specialists within a coordinated program.
Precautions
Use under specialized oncology supervision. Not a substitute for standard oncologic therapy.
Product information
- Manufacturer
- CIM, Havana
- Regulatory status
- Coordinated oncology program
Cancer & Oncology
CIMAvax-EGF®
Therapeutic vaccine targeting the EGF pathway for non-small cell lung cancer — registered in multiple countries.
VAXIRA® (Racotumomab)
Monoclonal antibody vaccine targeting NeuGcGM3 ganglioside antigens expressed on lung tumors.
HEBERSaVax®
Cuban biotech oncology product under investigation for cancer immunotherapy.